RxDoctor Payments Data

Sterlynn Patterson, NP

Family · Abilene, TXNPI 1578086682

Payments from drug & device makers

$1,124in general payments, 2019–2025

Across 78 payments — averaging $14.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$261
  • AstraZeneca$228
  • Amgen$207
  • E.r. Squibb & Sons, L.L.C.$115
  • Merck$75
  • Johnson & Johnson$58
  • plus $180 from 6 others

What the payments were for

  • Food & beverage$1,124100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,124 in reported general payments places this provider in the 70th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$73,225
Medicare patients
658
Services billed
1,024

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban214$202,803
XareltoRivaroxaban96$104,297
EntrestoSacubitril/Valsartan111$85,348
FarxigaDapagliflozin Propanediol91$67,521
Repatha SureclickEvolocumab91$66,802
JardianceEmpagliflozin45$40,896
BrilintaTicagrelor16$13,735
Praluent PenAlirocumab24$13,275
VascepaIcosapent Ethyl16$13,027
Ranolazine ErRanolazine86$6,952
Metoprolol Succinate334$4,788
Ezetimibe158$3,371
Icosapent Ethyl13$2,666
Rosuvastatin Calcium215$2,561
Midodrine Hcl30$2,067

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$18$202,803214 claims
Johnson & JohnsonXarelto$58$104,29796 claims
NovartisEntresto$261$85,348111 claims
AstraZenecaFarxiga, Brilinta$228$81,256107 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 15,456 family providers in Texas.

Other family in Abilene

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →